Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company that regularly issues news updates about its progress in developing therapies for autoimmune, inflammatory, and other immune-mediated diseases. The company’s announcements frequently focus on its lead program, SL-325, a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to target the clinically validated DR3/TL1A pathway in inflammatory bowel disease (IBD) and related conditions.
News about Shattuck often covers key clinical and regulatory milestones for SL-325, including Investigational New Drug (IND) submissions, IND clearance, initiation of Phase 1 clinical trials in healthy volunteers, and dosing of the first participants. The company also reports on preclinical data for SL-325, such as high-affinity binding to DR3, potent inhibition of TL1A binding, and favorable safety and receptor occupancy findings in non-human primate studies.
Investors following STTK can also expect updates on Shattuck’s broader DR3-focused pipeline, including multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and another biologically relevant target for IBD. Financing news is another recurring theme, with press releases detailing private placements, expected use of proceeds to advance SL-325 through Phase 1 and planned Phase 2 trials, and the company’s views on its cash runway.
Additional news items highlight Shattuck’s participation in medical and investor conferences, key opinion leader panels on DR3/TL1A biology and IBD, and changes to its Board of Directors associated with major financings. For readers tracking STTK, this page provides a centralized view of Shattuck’s clinical progress, scientific presentations, capital-raising activities, and governance developments as disclosed in its public communications.
Shattuck Labs (Nasdaq: STTK) reported Q2 2024 financial results and business highlights. Key points include:
1. Updated positive interim data from Phase 1B trial of SL-172154 with Azacitidine in HR-MDS and TP53m AML patients.
2. Enrollment ongoing in randomized Phase 1B dose-expansion cohort for frontline HR-MDS.
3. FDA granted Orphan Drug Designation for SL-172154 in AML treatment.
4. Q2 2024 financials: $105.3M cash and investments, $19.2M R&D expenses, $5.3M G&A expenses, $21.5M net loss ($0.42 per share).
5. Cash runway expected into 2026, beyond Phase 1 trial results for SL-172154.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotech company developing bi-functional fusion proteins for cancer and autoimmune disease treatment, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Dr. Taylor Schreiber, Shattuck's CEO, will engage in a fireside chat with BTIG analyst Kaveri Pohlman on August 5 at 2:00 p.m. ET. The company will also be available for one-on-one meetings during the conference. A live webcast of the fireside chat will be accessible to conference participants.
Shattuck Labs (Nasdaq: STTK), a clinical-stage biotechnology company focusing on bifunctional fusion proteins for cancer and autoimmune diseases, announced its inclusion in the Russell 2000® and Russell 3000® Indexes, effective July 1, 2024. This addition reflects the company's progress in advancing its lead candidate, SL-172154, in high-risk myelodysplastic syndromes (HR-MDS) and TP53-mutated acute myeloid leukemia (TP53m AML). The annual Russell U.S. Indexes reconstitution includes the 4,000 largest U.S. stocks, ranking them by market capitalization. The Russell Indexes are widely used by investment managers and institutional investors for index funds and benchmarking active investment strategies.
Shattuck Labs has revealed updated positive interim data from the Phase 1B clinical trial of SL-172154 combined with Azacitidine (AZA) for treating frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML).
The trial showed a 67% objective response rate (ORR) in HR-MDS patients, with a 58% complete remission rate, while frontline TP53m AML patients exhibited a 43% ORR and 33% complete remission with incomplete hematologic recovery.
SL-172154 demonstrated a manageable safety profile, with the most common adverse events being infusion-related reactions. The median overall survival for both patient groups has not yet been reached.
Shattuck is focusing on HR-MDS and TP53m AML due to competition and potential for accelerated approval pathways. The company will host a conference call on June 14, 2024, to discuss these findings further.
Shattuck Labs announced that its lead clinical candidate, SL-172154, has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of Acute Myeloid Leukemia (AML). This designation is awarded to drugs that address rare diseases affecting fewer than 200,000 people in the U.S. and provides benefits such as market exclusivity for seven years, tax credits for clinical trials, and waived application fees. The company plans to present additional data from the Phase 1B dose expansion clinical trial of SL-172154 at the European Hematology Association 2024 Congress.
Shattuck Labs will host an investor call and webcast on June 14, 2024, at 7:30 a.m. ET to discuss additional interim data from their Phase 1B dose expansion clinical trial of SL-172154 combined with Azacitidine (AZA) in treating frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) patients. The event, held during the European Hematology Association (EHA) 2024 Congress, will feature lead investigator Dr. Naval G. Daver from The University of Texas MD Anderson Cancer Center. The webcast will provide updates on safety and efficacy from the ongoing trial. Participants must register in advance to join the webcast, and a replay will be available for those unable to attend the live session.
Shattuck Labs (Nasdaq: STTK) will present new data from its Phase 1B trial of SL-172154 at the European Hematology Association (EHA) 2024 Congress. The trial, which combines SL-172154 with azacitidine (AZA), targets frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML). As of February 1, 2024, the combination therapy showed promising complete response (CR) rates and an acceptable safety profile. The HR-MDS cohort had a 65% objective response rate (ORR), while TP53m AML had a 36% ORR. The next data update is expected in the second quarter of 2024. Key safety concerns include infusion-related reactions and some severe treatment-emergent adverse events (TEAEs).
Shattuck Labs, Inc. (STTK) reported financial results for Q1 2024, highlighting progress in clinical trials for cancer treatments. They completed enrollment in Phase 1B cohorts for TP53m AML patients, presented preclinical data at AACR, and entered a collaboration with Ono Pharma. Financially, they have $114.6 million in cash and continue to focus on R&D.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
